Report

Stents Market Analysis

The stents market size in 2026 is estimated at USD 15.72 billion, growing from 2025 value of USD 15.05 billion with 2031 projections showing USD 19.52 billion, growing at 4.42% CAGR over 2026-2031. Sustained procedure volumes in coronary artery disease, wider adoption of minimally invasive peripheral interventions and steady product launches are keeping revenue on an upward trajectory. Consolidation among leading manufacturers is improving global reach and distribution efficiency, while health-system migration toward outpatient settings is reshaping procurement dynamics. Policymaker support for early discharge and bundled payments is accelerating purchases of devices that shorten hospital stays, driving hospitals and ambulatory surgical centers to upgrade stent inventories. In parallel, artificial-intelligence tools for vessel sizing and real-time decision support are enhancing implantation accuracy and reducing costly complications, reinforcing long-term demand in the stents market.

Global Stents Market Trends and Insights



Increasing Prevalence of Coronary & Peripheral Arterial Disease

Peripheral arterial disease affects an estimated 200-250 million people worldwide and shows marked variation in regional prevalence, ranging from 5.6% in North America to 14.5% in South-Central Asia. Demographic aging and persistent smoking and hypertension rates-contributing 45.6% and 35.1% of peripheral disease risk respectively-are sustaining a large pool of candidates for vascular interventions. As diagnostics improve and awareness rises in emerging economies, demand for both coronary and peripheral stents strengthens, positioning disease prevalence as the prime long-term growth catalyst for the stents market.

Rapid Uptake of Transradial PCI & Day-Case Procedures

Transradial access adoption climbed from 15.9% to 69.1% across recent study periods, reducing bleeding events and enabling same-day discharge protocols. The American Heart Association endorsed transradial approaches for peripheral interventions in 2025, broadening clinical applications. Ambulatory surgical centers billing for PCI increased from 30 sites in 2019 to 65 in 2023, illustrating procedure migration away from inpatient settings.These patterns are accelerating device demand among outpatient providers and reinforcing value-based care initiatives in the stents market.

Stringent Multi-Region Approval Timelines

Manufacturers must reconcile divergent regulatory pathways as the FDA aligns Quality System Regulation amendments with ISO 13485 while Europe enforces Medical Device Regulation, extending time-to-market. Emerging countries introduce additional clinical evidence requirements, forcing companies to stagger launches and increasing compliance costs. Large incumbents with robust regulatory teams can absorb delays, but smaller innovators face barriers that may slow new entrants into the stents market.

Other drivers and restraints analyzed in the detailed report include:

Technological Shift to Polymer-Free DES & BioresorbablesAI-Driven Precision Sizing & Deployment PlatformsHigh and Rising Product Recall Costs

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Coronary stents accounted for 54.60% of stents market share in 2025 on the back of entrenched procedure volumes in multivessel disease. Drug-eluting models featuring ultrathin struts and biodegradable polymers remain the default choice, while bare-metal designs fulfill niche needs that require shorter dual antiplatelet therapy. Peripheral stents, however, are forecast to grow at a 7.18% CAGR, driven by expanding treatment indications for iliac and femoropopliteal lesions and better device trackability in tortuous anatomy. Abbott's FDA nod for a bioresorbable scaffold below the knee illustrates momentum toward "leave nothing behind" options in peripheral disease.

The stents market size for peripheral interventions is projected to expand steadily as screening programs and duplex ultrasound accessibility improve in emerging economies. Stent grafts for complex aortic aneurysms continue to evolve with branched and fenestrated designs that reduce endoleak risk, while neurovascular flow-diverters capture attention for wide-necked aneurysms. Manufacturers are integrating hydrophilic coatings and AI-enabled deployment feedback to improve outcomes in difficult vascular territories.

Metallic biomaterials remained the backbone of the stents market, claiming 62.70% revenue in 2025 because cobalt-chromium alloys offer high radial strength and corrosion resistance. Stainless steel retains a cost advantage in price-sensitive segments. Nonetheless, polymeric scaffolds are the fastest-advancing category at an 8.54% CAGR, reflecting clinical enthusiasm for biodegradable solutions that minimize chronic inflammation. Magnesium-based constructs exhibit 2.8% platelet adherence versus 5.8% for stainless steel in preclinical models, indicating lower thrombogenicity.

Natural biomaterial coatings such as recombinant humanized collagen foster rapid endothelialization and are likely to carve out specialized niches for drug-free devices. Controlled-release polymer matrices now enable synchronized drug elution with scaffold resorption, addressing previous concerns over mechanical integrity. Economies of scale and manufacturing advances will continue to lower production costs, helping premium polymeric devices penetrate mainstream segments of the stents market.

The Stents Market Report is Segmented by Product (Coronary Stents [Drug-Eluting Stents and More], Peripheral Stents, and Stent Grafts & Implants), Material (Metallic Biomaterials, Polymeric Biomaterials, and More), Application (Coronary Artery Disease, Peripheral Artery Disease and More), End User (Hospitals, Ambulatory Surgical Centers and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America's stents market size stood at USD 5.36 billion in 2026, driven by 500,000 annual PCI procedures, sophisticated catheter laboratories and early adoption of AI-guided sizing tools. Favorable reimbursement and clinical guideline updates that endorse day-case PCI support continuous device refresh cycles. Canada's universal coverage and hospital capital budgets are more measured, yet procedure volumes benefit from aging demographics and rising diabetes prevalence.

Europe displays steady single-digit revenue growth as MDR compliance ensures high product quality and as national health systems favour cost-effectiveness metrics. Germany, France and the United Kingdom remain top spenders, while Southern and Eastern European countries are upgrading cath-lab fleets through EU infrastructure funds. The stents market share across Western Europe is tempered by price controls, but value-based procurement is beginning to reward technologies that shorten dual antiplatelet therapy and reduce rehospitalization.

Asia-Pacific is the largest incremental contributor to future unit demand, with China alone performing over 1 million coronary interventions in 2024. Reforms streamlining local approval for innovative devices are shortening launch timelines, although province-specific catalog pricing creates margin pressures. India's national insurance scheme broadens access to PCI, while Japan maintains premium pricing for polymer-free and ultra-thin stents due to rapid ageing. Southeast Asian nations are scaling cardiac centers, and public-private partnerships in Indonesia and Vietnam are accelerating infrastructure deployment. Collectively, these trends anchor Asia-Pacific as the fastest-growing region within the stents market.

List of Companies Covered in this Report:

Abbott Laboratories Boston Scientific Medtronic Beckton Dickinson B. Braun Terumo BIOTRONIK MicroPort Cook Group Elixir Medical Allium Medical Cordis Lepu Medical Meril Life Sciences JenaValve Technology SMT SINOMED Alvimedica Endologix

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support